Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2022 Jul 1;31(7):1460–1465. doi: 10.1158/1055-9965.EPI-21-1234

Figure 1.

Figure 1.

Hazard ratios (HR) and 95% confidence intervals (CI) for the association between ever use of 5-ARIs and prostate cancer outcomes. (A) HRs and 95% CIs for all 38,037 men in the study population and the subset of 22,424 men who had PSA screening at baseline. (B) HRs and 95% CIs for 4,824 men who have a family history fo prostate cancer in their father or brother. (Note: High-grade is Gleason score 4+3 and higher; low-grade is Gleason score 3+4 and lower.)